Co-prescribing of Central Nervous System–Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization

Abstract

Background:

Anxiety and chronic pain are common comorbidities in patients with chronic obstructive pulmonary disease (COPD), which are frequently managed with benzodiazepines (BZDs) and opioids, respectively.

Objective:

The purpose of this study was to determine whether different combinations of opioids, BZD, and their substitutes—gabapentinoids (GABA) and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs)—are associated with lower risk of acute respiratory events in COPD patients with co-occurring chronic pain and anxiety.

Methods:

This retrospective cohort study used a nationally representative sample of Medicare beneficiaries with COPD, chronic pain, and anxiety. Patients were grouped based on drug combination (opioid + BZD/Z-hypnotics, opioid + GABA, opioid + SSRI/SNRI, BZD/Z-hypnotics + GABA, BZD/Z-hypnotics + SSRI/SNRI, GABA + SSRI/SNRI, or ≥3 drugs). The primary outcome was emergency room (ER) visit or hospitalization due to acute respiratory events assessed up to 180 days following initiation of drug combination. Overdose secondary to central nervous system (CNS)–related drugs was also assessed up to 180 days following initiation of drug combination.

Results:

The drug combination opioid + GABA was associated with decreased risk for ER visit (hazard ratio [HR] = 0.73; 95% CI = 0.61-0.87) and hospitalization (HR = 0.69; 95% CI = 0.55-0.85). Opioid + SSRI/SNRI also showed decreased risk for ER visit (HR = 0.84; 95% CI = 0.71-0.99). There was no significant difference in risk for CNS-related drug overdose among different drug combinations compared with opioid + BZD/Z-hypnotics.

Conclusion and Relevance:

Opioids in combination with GABA and SSRI/SNRI demonstrate relatively lower risk for acute respiratory events among patients with COPD and comorbid chronic pain and anxiety. The findings emphasize the need for multimodal management in this vulnerable population.

Keywords

COPD opioids benzodiazepines gabapentinoids selective serotonin reuptake inhibitors serotonin and norepinephrine reuptake inhibitors

Get full access to this article

View all access options for this article.

References

Carmona-Pírez

Poblador-Plou

Ioakeim-Skoufa

, et al. Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort. Sci Rep. 2021;11(1):4784. doi:10.1038/s41598-021-83964-w.

Fuentes-Alonso

López-de-Andrés

Palacios-Ceña

, et al. COPD is associated with higher prevalence of back pain: results of a population-based case-control study, 2017. J Pain Res. 2020;13:2763-2773. doi:10.2147/JPR.S271713.

Hansen

Molsted

Ekholm

Hansen

. Pain prevalence, localization, and intensity in adults with and without COPD: results from the Danish Health and Morbidity Survey (a self-reported survey). Int J Chron Obstruct Pulmon Dis. 2020;15:3303-3311. doi:10.2147/COPD.S275234.

Lee

Goldstein

Brooks

. Chronic pain in people with chronic obstructive pulmonary disease: prevalence, clinical and psychological implications. Chronic Obstr Pulm Dis. 2017;4(3):194-203. doi:10.15326/jcopdf.4.3.2016.0172.

Lewthwaite

Williams

Baldock

Williams

. Systematic review of pain in clinical practice guidelines for management of COPD: a case for including chronic pain? Healthcare (Basel). 2019;7(1):15. doi:10.3390/healthcare7010015.

Eisner

Blanc

Yelin

, et al. Influence of anxiety on health outcomes in COPD. Thorax. 2010;65(3):229-234. doi:10.1136/thx.2009.126201.

Roberts

Mapel

Thomson

. The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2015;7:173-184. doi:10.2147/CEOR.S80424.

Pattinson

. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758. doi:10.1093/bja/aen094.

Obiora

Hubbard

Sanders

Myles

. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163. doi:10.1136/thoraxjnl-2012-202374.

10.

Vozoris

Fischer

Wang

, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183-192. doi:10.1007/s40266-013-0056-1.

11.

Park

C-H

Hsu

W-T

, et al. Use of opioids and outcomes of pneumonia: results from the US Nationwide Inpatient Sample. J Acute Med. 2021;11(4):113-128. doi:10.6705/j.jacme.202112_11(4).0001.

12.

Baillargeon

Singh

Kuo

Raji

Westra

Sharma

. Association of opioid and benzodiazepine use with adverse respiratory events in older adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2019;16(10):1245-1251. doi:10.1513/AnnalsATS.201901-024OC.

13.

Brady

McCauley

Back

. Prescription opioid misuse, abuse, and treatment in the United States: an update. Am J Psychiatry. 2016;173(1):18-26. doi:10.1176/appi.ajp.2015.15020262.

14.

Dowell

Haegerich

Chou

. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464.

15.

Bohnert

ASB

Guy

Jr Losby

. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline. Ann Intern Med. 2018;169(6):367-375. doi:10.7326/m18-1243.

16.

Jeffery

Hooten

Jena

Ross

Shah

Karaca-Mandic

. Rates of physician coprescribing of opioids and benzodiazepines after the release of the Centers for Disease Control and Prevention guidelines in 2016. JAMA Netw Open. 2019;2(8):e198325. doi:10.1001/jamanetworkopen.2019.8325.

17.

Gorfinkel

Hasin

Saxon

, et al. Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014-2018. J Pain. 2022. doi:10.1016/j.jpain.2022.01.006.

18.

Esechie

Kuo

Y-F

Goodwin

Westra

Raji

. Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study. BMJ open. 2021;11(11):e053487. doi:10.1136/bmjopen-2021-053487.

19.

Jones

Lurie

Throckmorton

. Effect of US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Intern Med. 2016;176(3):399-402. doi:10.1001/jamainternmed.2015.7799.

20.

Strickler

Kreiner

Halpin

Doyle

Paulozzi

. Opioid prescribing behaviors—prescription behavior surveillance system, 11 states, 2010-2016. MMWR Surveill Summ. 2020;69(1):1-14. doi:10.15585/mmwr.ss6901a1.

21.

Shen

Hincapie-Castillo

Vouri

Dewar

Sumfest

Goodin

. Prescription patterns of adjuvant pain medications following an opioid supply restriction law: an interrupted time series analysis. Med Care. 2022;60(6):432-436. doi:10.1097/mlr.0000000000001719.

22.

American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810-833. doi:10.1097/ALN.0b013e3181c43103.

23.

Dale

Stacey

. Multimodal treatment of chronic pain. Med Clin North Am. 2016;100(1):55-64. doi:10.1016/j.mcna.2015.08.012.

24.

Monticone

Ferrante

Rocca

Baiardi

Farra

Foti

. Effect of a long-lasting multidisciplinary program on disability and fear-avoidance behaviors in patients with chronic low back pain: results of a randomized controlled trial. Clin J Pain. 2013;29(11):929-938. doi:10.1097/AJP.0b013e31827fef7e.

25.

Kamper

Apeldoorn

Chiarotto

, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev. 2014;(9):CD000963. doi:10.1002/14651858.CD000963.pub3.

26.

Borys

Lutz

Strauss

Altmann

. Effectiveness of a multimodal therapy for patients with chronic low back pain regarding pre-admission healthcare utilization. PLoS One. 2015;10(11):e0143139. doi:10.1371/journal.pone.0143139.

27.

Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. 2022. Accessed July 7, 2022. https://www.apa.org/depression-guideline#.

28.

Pauly

Delcher

Slavova

Lindahl

Talbert

Freeman

. Trends in gabapentin prescribing in a commercially insured U.S. adult population, 2009-2016. J Manag Care Spec Pharm. 2020;26(3):246-252. doi:10.18553/jmcp.2020.26.3.246.

29.

Hong

JSW

Atkinson

Al-Juffali

, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022;27(3):1339-1349. doi:10.1038/s41380-021-01386-6.

30.

Baldwin

den Boer

Lyndon

Emir

Schweizer

Haswell

. Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol. 2015;29(10):1047-1060. doi:10.1177/0269881115598411.

31.

Montgomery

Emir

Haswell

Prieto

. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29(10):1223-1230. doi:10.1185/03007995.2013.820694.

32.

Medicare Sample Group Indicator. Research Data Assistance Center. Accessed July 7, 2022. https://resdac.org/cms-data/variables/medicare-sample-group-indicator.

33.

What Medicare Covers. Center for Medicare and Medicaid Services. Accessed July 7, 2022. https://www.medicare.gov/what-medicare-covers.

34.

Chronic Conditions Data Warehouse. Accessed July 7, 2022. https://www2.ccwdata.org/web/guest/condition-categories.

35.

Maier

Buller

Philipp

Heuser

. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61-68. doi:10.1016/0165-0327(88)90072-9.

36.

American Psychiatric Association. DSM-5 diagnostic classification. In: Diagnostic and Statistical Manual of Mental Disorders. DSM Library. American Psychiatric Association; 2013.

37.

Brenes

Miller

Stanley

Williamson

Knudson

McCall

. Insomnia in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2009;17(6):465-472. doi:10.1097/jgp.0b013e3181987747.

38.

Papadimitriou

Linkowski

. Sleep disturbance in anxiety disorders. Int Rev Psychiatry. 2005;17(4):229-236. doi:10.1080/09540260500104524.

39.

Uhde

Cortese

Vedeniapin

. Anxiety and sleep problems: emerging concepts and theoretical treatment implications. Curr Psychiatry Rep. 2009;11(4):269-276. doi:10.1007/s11920-009-0039-4.

40.

Bain

. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother. 2006;4(2):168-192. doi:10.1016/j.amjopharm.2006.06.006.

41.

George

. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep. 2000;23(suppl 1):S31-S35.

42.

Ringdahl

Pereira

Delzell

. Treatment of primary insomnia. J Am Board Fam Pract. 2004;17(3):212. doi:10.3122/jabfm.17.3.212.

43.

Pottie

Thompson

Davies

, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.

44.

Sharma

Weir

Samanani

, et al. Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study. BMJ Open. 2019;9(9):e030858. doi:10.1136/bmjopen-2019-030858.

45.

Stege

Vos

van den Elshout

Richard Dekhuijzen

van de Ven

Heijdra

. Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med. 2008;102(6):801-814. doi:10.1016/j.rmed.2007.12.026.

46.

Ray

Chung

Murray

Malow

Daugherty

Stein

. Mortality and concurrent use of opioids and hypnotics in older patients: a retrospective cohort study. PLoS Med. 2021;18(7):e1003709. doi:10.1371/journal.pmed.1003709.

47.

Richelson

. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76(5):511-527. doi:10.4065/76.5.511.

48.

Divo

Cote

de Torres

, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-161. doi:10.1164/rccm.201201-0034OC.

49.

Miller

Edwards

Agustí

, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-1384. doi:10.1016/j.rmed.2013.05.001.

50.

Westerik

Metting

van Boven

Tiersma

Kocks

Schermer

. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18(1):31. doi:10.1186/s12931-017-0512-2.

51.

Elixhauser

Steiner

Harris

Coffey

. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27. doi:10.1097/00005650-199801000-00004.

52.

Mapel

Dutro

Marton

Woodruff

Make

. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11:43. doi:10.1186/1472-6963-11-43.

53.

Gilron

Bailey

Holden

Weaver

Houlden

. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324-1334. doi:10.1056/NEJMoa042580.

54.

Wang

Yang

Shen

Luo

. Morphine and pregabalin in the treatment of neuropathic pain. Exp Ther Med. 2017;13(4):1393-1397. doi:10.3892/etm.2017.4102.

55.

Jang

Kwon

Hwang

, et al. Comparison of the efficacy of a gabapentinoid with an opioid versus an opioid alone in patients with spinal cord stimulation. Pain Physician. 2018;21(4):E429-E434.

56.

Asmundson

Katz

. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009;26(10):888-901. doi:10.1002/da.20600.

57.

McWilliams

Cox

Enns

. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003;106(1-2):127-133. doi:10.1016/s0304-3959(03)00301-4.

58.

Molina

Fairman

Sclar

. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthc Patient Saf. 2018;10:37-43. doi:10.2147/DHPS.S151073.

59.

Bair

Robinson

Katon

Kroenke

. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433-2445. doi:10.1001/archinte.163.20.2433.

60.

Curry

Dang

Sima

Abdullaziz

Del Fabbro

. Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study. Ann Palliat Med. 2021;10(3):2505-2511. doi:10.21037/apm-20-1455.

61.

Overholser

Foster

. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(suppl 11):S276-S287.

62.

Yunusa

Gagne

Yoshida

Bykov

. Risk of opioid overdose associated with concomitant use of oxycodone and selective serotonin reuptake inhibitors. JAMA Netw Open. 2022;5(2):e220194. doi:10.1001/jamanetworkopen.2022.0194.

63.

Doyle

Palmer

Johnson

, et al. Association of anxiety and depression with pulmonary-specific symptoms in chronic obstructive pulmonary disease. Int J Psychiatry Med. 2013;45(2):189-202. doi:10.2190/PM.45.2.g.

64.

Collet

Shapiro

, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008;178(9):913-920. doi:10.1164/rccm.200804-619OC.

65.

Bratek

Zawada

Beil-Gawełczyk

, et al. Depressiveness, symptoms of anxiety and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary disease (COPD): possible associations with inflammation markers: a pilot study. J Neural Transm (Vienna). 2015;122(suppl 1):S83-S91. doi:10.1007/s00702-014-1171-9.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.01 MB